Skip to main content
Premium Trial:

Request an Annual Quote

Sequencing Startup Omniome Closes $60M Series C Financing

NEW YORK – Omniome announced Thursday that it has raised $60 million in Series C financing, led by Madrone Capital Partners.

The San Diego-based firm said in a statement that it would use the funds to "accelerate late-stage product development and launch planning," continue optimizing its "scar-free" sequencing biochemistry, and further develop its instrument. It will also expand its workforce, especially in manufacturing, engineering, development, customer support, and commercial operations.

"The goal and vision have always been to develop a disruptive sequencing technology taking into account accuracy, speed, throughput, and cost," Omniome Executive Chairman Ken Song said in a statement. "The team's success in advancing product development across these dimensions has attracted considerable interest from top-tier investors."

The San Diego-based DNA sequencing firm has now raised at least $145 million, it said in a statement, with $60 million from its Series B financing round in 2018.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.